ArticleResearch in pharmaceutical sciences2026
Discovery of PIM-1 kinase inhibitors from marine natural products through machine learning and structure-based screening.
Article in Research in pharmaceutical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: PIM-1 kinase, a serine/threonine kinase implicated in several cancers, has emerged as a promising yet underexplored target for anticancer therapy. This study aimed to identify the potential of PIM-1 inhibitors from marine natural products by integrating machine learning (ML)-based quantitative structure-activity relationship (QSAR) modeling with structure-based virtual screening. Experimental approach: Eleven ML models were developed and evaluated using experimentally validated ChEMBL data. The best-performing model was used to screen the Chemical Marine Natural Product Database (CMNPD), yielding 15 candidate compounds. Molecular docking prioritized four hits based on similarity of binding interactions at the catalytic site to the co-crystallized reference ligand, rather than on docking score alone. These hits were further assessed using 100 ns molecular dynamics (MD) simulations and MM/GBSA binding free-energy calculations. ADMET profiling was also performed to evaluate pharmacokinetic and toxicity properties. Findings/Results: Among the screened compounds, Hit-1 (CMNPD11687) emerged as the lead candidate. It showed stable binding throughout MD simulations, with an average RMSD of 4.10 ± 1.67 Å, low atomic fluctuations (RMSF), and favorable binding free energy (ΔG- Conclusion and implications: These findings identified CMNPD11687 as a promising marine-derived scaffold for PIM-1 inhibition and demonstrated the value of combining ML-driven screening with molecular simulation to accelerate early-stage anticancer drug discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.